Everything below concerns PPARδ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-10. Numbers and descriptions here follow the published literature rather than marketing material.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
=== Awards and honours === Scrutton was awarded the Colworth Medal in 1999 from the Biochemical Society; the Enzyme Chemistry Award (Charmian Medal) from the Royal Society of Chemistry in 2002; the Rita and John Cornforth Award from the Royal Society of Chemistry in 2009; the Interdisciplinary Prize from the Royal Society of Chemistry in 2019. Scrutton was elected a Fellow of the Royal Society (FRS) in 2020; Fellow of the Royal Society of Chemistry (FRSC) in 1996; a Fellow of the Royal Society of Biology (FRSB) in 2009; a Member of the Lister Institute in 2004. He is recipient of a number of academic awards including: Sambrooke Exhibition Prize (King's College London, University of London, 1983); William Robson Prize (King's College London, University of London, 1985); Benefactors' Scholarship (St John's College, University of Cambridge, 1985); Henry Humphreys Research Prize / Research Fellowship (St John's College, University of Cambridge, 1989).
While these protection strategies do slightly reduce the exposure, they provide almost no protection from externally penetrating gamma radiation, which is the cause of acute radiation syndrome and can be extremely lethal in high dosages. Naturally, shielding the entire body from high-energy gamma radiation is optimal, but the required mass to provide adequate attenuation makes functional movement nearly impossible. Recent scientific studies have shown the feasibility of partial body shielding as a viable protection strategy against externally penetrating gamma radiation. The concept is based in providing sufficient attenuation to only the most radio-sensitive organs and tissues in efforts to defer the onset of acute radiation syndrome, the most immediate threat to humans from high doses of gamma radiation. Acute radiation syndrome is a result of irreversible bone marrow damage from high-energy radiation exposure. Due to the regenerative property of hematopoietic stem cells found in bone marrow, it is only necessary to protect enough bone marrow to repopulate the exposed areas of the body with the shielded supply. Because 50% of the body's supply of bone marrow is stored in the pelvic region which is also in close proximity to other radio-sensitive organs in the abdomen, the lower torso is a logical choice as the primary target for protection.
S-Methylcysteine sulfoxide is an organosulfur compound with the formula CH3S(O)CH2CH(NH2)CO2H. It is the sulfoxide of S-methylcysteine. It contributes to the flavor of onions (Allium sp.). The compound is usually encountered as one diastereoisomer, the (R)- and (S)-configurations at the carbon and sulfur stereocenters, respectively. The S-methyl part of the name refers to the location of the methyl group on sulfur. Although odorless, S-methylcysteine sulfoxide is acted upon by alliinase and lachrymatory-factor synthase. S-Methylcysteine sulfoxide is produced from glutathione. Related compounds are the unsaturated sulfoxides S-trans-prop-1-enyl cysteine sulfoxide and S-propyl cysteine sulfoxide, both found also in onions, and S-allyl cysteine sulfoxide, typically found in garlic.
Sources: en.wikipedia.org
Reversing the decision, the Supreme Court ruled that a defendant in a selective prosecution case had to make a "credible showing" of evidence that the prosecution policy in question was intentionally discriminatory. The court ruled that Bass did not do so because he failed to show that similar cases with those different races were treated differently. Specifically, the Court rejected Bass's use of national statistics and held that they were not representative of cases. Both cases have been criticized for perpetuating racially motivated legal standards. It has been suggested that the current standard is impossible to meet for selective prosecution claims because the relevant data may not exist, or the prosecution may have sole access to it.
Charles R. Drew Middle School in the Los Angeles Unified School District Charles R. Drew Middle School in Talladega County Schools Charles R. Drew Transition Center in Detroit Public Schools Community District Dr. Charles R. Drew Science in Buffalo Public Schools Charles R. Drew K-8 Center in Miami-Dade County Public Schools Charles Drew Elementary Magnet in Broward County Public Schools Bluford Drew Jemison S.T.E.M Academy in Baltimore Bluford Drew Jemison STEM Academy West in Baltimore City Public Schools Dr. Charles R. Drew Elementary School in Montgomery County Public Schools Charles Drew Elementary School in Washington, D.C. Dr. Charles R. Drew Elementary in Arlington Public Schools Dr. Charles Drew Elementary School in New Orleans Charles R. Drew Charter School in Atlanta Dr. Charles Drew Academy in Ecorse, Michigan Drew Academy in Aldine Independent School District Charles R. Drew Elementary School in Crosby Independent School District Dr. Charles R. Drew College Preparatory Academy in San Francisco Unified School District Charles R Drew ELC 1 in The Bronx
For most of its history, Grace's main business was cargo shipping, operating the Grace Line. To move cargo from Peru to North America and Europe, including guano and sugar, and noticing the need for other goods to be traded, William Grace founded a shipping division. Grace Line began service in 1882, with ports of call between Peru and New York. Regular steamship service was established in 1893, with a subsidiary called the New York & Pacific Steamship Co., that operated under the British flag. Ships built outside the United States before 1905 were banned from the US registry. US-flag service began in 1912 with the Atlantic and Pacific Steamship Company. The activities of both companies and the parent firm were consolidated into the Grace Steamship Company beginning in 1916. The firm originally specialized in traffic to the west coast of South America then later expanded into the Caribbean.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.